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Hyaluronan (HA), a major component of the extracellular matrix (ECM), plays a key role in
regulating inflammation. Inflammation is associated with accumulation and turnover of HA
polymers by multiple cell types. Increasingly through the years, HA has become recog-
nized as an active participant in inflammatory, angiogenic, fibrotic, and cancer promoting
processes. HA and its binding proteins regulate the expression of inflammatory genes, the
recruitment of inflammatory cells, the release of inflammatory cytokines, and can attenuate
the course of inflammation, providing protection against tissue damage. A growing body of
evidence suggests the cell responses are HA molecular weight dependent. HA fragments
generated by multiple mechanisms throughout the course of inflammatory pathologies,
elicit cellular responses distinct from intact HA. This review focuses on the role of HA in
the promotion and resolution of inflammation.
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INTRODUCTION
The association of increased HA deposition into the extracellular
matrix (ECM) after tissue injury and during inflammatory disease
has been recognized for over 25 years. Increased accumulation of
HA has been demonstrated: in joint tissue of rheumatoid arthritis
(RA) patients (1); in lung disease, both in humans (2) and animal
experimental models (3–7); in inflammatory liver disease; during
vascular disease (8, 9); in rejected kidney transplants (10) as well
renal tissue of patients experiencing diabetic nephropathy (11); in
the intestine of patients undergoing flares of inflammatory bowel
disease (IBDs) (12), and mice with experimental colitis (13). Ini-
tially, HA was considered merely an inert space filling substance
that had the capacity to surround itself with water molecules thus
maintaining structure and preventing dehydration. The accompa-
nying edema that occurs with HA deposition frequently impairs
organ function.
Beyond the physical properties of a structural ECM molecule,
however, it has become increasingly clear that HA provides cellular
cues to regulate inflammation and tissue repair. The mystery is how
and why does such a ubiquitous molecule produced in abundance
by all vertebrates in every body tissue, foster inflammation under
particular circumstances. This review focuses on discussing what is
known regarding the mechanisms through which HA recruits and
activates leukocytes in pathological inflammatory settings. Dis-
cussion will center on: (1) how HA is organized into a leukocyte
recruiting matrix; (2) how it is degraded into fragments that are
capable of signaling inflammatory responses via specific receptors;
and (3) what are the known downstream effects and consequences
of such activation. Over the past 15 years specific pathways sig-
naled by HA have been defined and these have shaped the view of
HA as a regulator of innate and acquired immunity, providing us
with the concept that damaged ECM provides cues to surround-
ing cells to drive a protective response. In a dysregulated state,
for example, the excess production of a pathological matrix, or
the overproduction of HA fragments, HA is likely to contribute
to chronic inflammatory conditions such as in RA, inflammatory
bowels disease, atherosclerosis, and diabetes.
HYALURONAN IS A SIZE-DEPENDENT MEDIATOR OF
INFLAMMATION
Data during the past two decades have established the fact that
many of the cellular and biochemical processes mediated by HA are
dependent upon the distribution of its molecular mass. HA poly-
mers are comprised of repeating disaccharide units of glucuronic
acid and N -acetyl glucosamine joined by alternating (β-1,3 and
β-1,4) glycocidic linkages free of a protein core. An integral com-
ponent of the ECM, HA polymers are traditionally considered as
solvating, structural macromolecules largely responsible for sup-
porting tissue integrity due to substantial viscoelastic properties
(14). In normal tissues, HA exists as high-molecular-weight HA
(HMW-HA) often with an average molecular weight of ~107 Da
that is capable of occupying a 1000-fold volume of water (15).
HMW-HA is one of the principle components of the glycocalyx
and is able to spatially exclude other molecules and cells, func-
tioning as an anti-angiogenic factor. Several studies have shown
that HMW-HA inhibits angiogenesis through reducing both the
proliferation and migration of endothelial cells (7, 16, 17). At the
extracellular surface HMW-HA interacts with surface receptors,
prevents immune cell recognition, and blocks phagocytosis by
macrophages (18, 19).
In cases of inflammation and tissue injury, HA is significantly
more polydisperse and contains a variety of HA polymers with
overlapping lengths and functions. Generally speaking, HA with
an average molecular mass <500 kDa can be considered a frag-
ment, although the molecular properties of such a size are quite
different than those of a 50 kDa fragment. In most studies, the
indicated sizes of HA represent the average molecular weight of
a polydisperse distribution, and the preparations of HA used are
not homogeneous with respect to size. As such, care must be taken
when considering the effects of different polymer sizes.
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Large HA polymers function as tissue integrity signals and serve
to suppress the inflammatory response. As HMW-HA becomes
depolymerized in inflammatory conditions such as RA, it loses its
lubricant properties as noted in the synovial fluid of RA patients (1,
20). While it is unclear whether the generation of HA fragments is
the result of HA catabolic enzymes, reactive oxygen species (ROS),
a truncated product of the HA biosynthetic enzymes, or a com-
bination of these mechanisms, it is clear that HA polymers of
specific sizes contain distinct biological activities. HA exists as
both a pro- and anti-inflammatory molecule in vivo, and these
contradictory functions depend upon polymer length and which
receptors the oligosaccharides engage. HMW-HA elicits protective
anti-inflammatory effects that protect lung epithelial cells from
apoptosis and is protective against liver injury, acting to reduce
pro-inflammatory cytokines in a T-cell mediated injury model
(3, 21). In regulatory T-cells, HMW-HA stimulates STAT5 signal-
ing through CD44 crosslinking, promoting their maintenance and
thereby inhibiting their proliferation. Conventional T-cell precur-
sors stimulated with HMW-HA produce IL-10, and infusion of
these cells attenuates the disease course in a murine model of
colitis (22, 23).
The presence of cable-like structures comprised of HA, associ-
ated with binding proteins, has been noted in several inflammatory
conditions including IBDs, atherosclerosis, diabetic nephropathy,
and chronic kidney disease (24–29). HA polymers of indetermi-
nate sizes originate from the surface of multiple cells and coa-
lesce into large HA cables capable of spanning multiple cells and
reaching several millimeters in length (30). The presence of HA
cables at sites of tissue inflammation can still function as an anti-
inflammatory polymer. Monocytes adhere tightly to the HA cables
regardless of their activation state, and following adhesion the dis-
tribution of CD44 on the monocyte cell surface polarizes to form a
“cap”while a portion of the HA cable is internalized (Figure 1). HA
cables can function as a biological sink for monocytes and platelets,
and these interactions likely modulate pro-inflammatory stimuli
[see review in Ref. (31)]. The presence of HA cables is not unique
to the inflammatory process, and cables are formed in response to
ER stress, cycloheximide treatment, and viral infection (24, 32, 33).
HA catabolic hyaluronidase enzymes on the cell surface of
platelets are capable of depolymerizing HA at neutral pH, and
the subsequent fragments induce monocyte activation (34). HA
fragments have also been shown to have a number of pro-
inflammatory effects such as activation of macrophages and den-
dritic cells as well as stimulating transcription of inflammation-
related genes including TNF-α, IL-12, IL-1β, and matrix met-
alloproteinases (35–37). However, it is important to note that
some of the pro-inflammatory effects attributed to HA frag-
ments likely result from contaminants in the HA preparations
used. Caution should be taken with respect to the source and
purity of HA for such studies. Polydisperse HA fragments with
an average molecular weight of 200-kDa have been shown to
stimulate chemokines, cytokines, growth factors, proteases, and
nitric oxide by macrophages (38–44). In some cases, the sig-
naling pathways engaged by HA fragments have been partially
defined. Murine macrophages stimulated by HA fragments can
activate the inhibitor of nuclear factor-κB pathway,which increases
the expression of interleukin-1β and TNF-α (43). In smooth
muscle cells, HA fragments promote cell-cycle progression by
CD44-dependent activation of the Rac/ERK pathway, while the
HMW-HA is inhibitory (45).
Although most of the work on low-molecular-weight HA
fragments initially illustrated a pro-inflammatory response, a
number of studies have shown that HA fragments can also be
protective. In a DSS-induced murine model of colitis, intraperi-
toneal injection of polydisperse HA <750-kDa protects colonic
epithelium in a Toll-like receptor (TLR) 4-dependent manner
FIGURE 1 | Capping of CD44 on leukocytes. (A) Monocytes bind to
HA cables (green) produced by M-SMC in response to poly I:C. CD44
(red) is dispersed on the monocyte surface. (B) After 15 min
incubation at 37°C, CD44 (red) is capped to one pole on the
leukocytes, HA cables appear ragged (center panel) and HA is
internalized. (Nuclei are blue).
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(46). Intermediate-molecular-weight HA <200 kDa stimulates
the expression of human β-defensin 2 (HBD2) in human ker-
atinocytes, through TLRs 2 and 4 (47). More recently, our labora-
tory has shown that HA-dependent induction of HBD2 in intesti-
nal epithelial cells and in the colonic mucosa of mice is highly size
specific. The strongest induction was observed with HA of 35-kDa
average molecular weight, and was TLR 4 dependent (48).
HYALURONAN-BINDING PROTEINS AND THEIR ROLES
IN INFLAMMATION
While many of the HA-binding proteins have been previously
reviewed elsewhere (49), several HA-binding proteins are of par-
ticular importance with regard to inflammatory processes and will
be discussed in the following section. The repeating nature of HA
oligosaccharides and the specificity of protein–HA interactions
likely dictate many of the mechanisms by which HA functions as
either a pro- or anti-inflammatory molecule. The ECM, comprised
predominantly of proteoglycans, glycoproteins, and collagens, is
increasingly being viewed as having both structural and regula-
tory roles. Collectively, the ability of HA to function as either
a pro- or anti-inflammatory molecule is dependent upon its
size, microenvironment, localization, and availability of specific
binding partners.
Inter-alpha-trypsin inhibitor (IαI) is one member in a family of
serum proteoglycans secreted by the liver that function as serum
protease inhibitors. It is reported to circulate in serum at con-
centrations between 150 and 500µg/mL, comprises ~5% of total
protease inhibitory activity of plasma, and elevated levels reported
in inflammatory pathologies (50, 51). This proteoglycan is unusual
as a single chondroitin sulfate chain is covalently attached to
bikunin, a serine protease inhibitor, and another family of proteins
termed heavy chain (HC) (HC1, HC2, HC3) are covalently linked
to the chondroitin sulfate chain through an ester bond between C-
terminal aspartate and the 6-hydroxyl of an N-acetylgalactosamine
(52–54). In several inflammatory diseases, such as Crohn’s disease,
asthma, osteo- and rheumatoid-arthritis (OA, RA), the increase
in HA production is commensurate with increased levels of IαI
heavy chains covalently attached to HA. In the case of Crohn’s dis-
ease, heavy chains of IαI are specifically associated with HA cable
structures and are highly adhesive for naïve unactivated leukocytes,
possibly in competition with inflammatory receptors (12, 55). Fur-
ther, soluble HA containing HC1 and pentraxin 3 has been shown
to induce apoptosis of activated, but not resting, neutrophils and
macrophages (56). IαI and heavy chains are present at high levels
in the synovial fluid of RA and OA patients, and HC complexes
linked to HA have been shown to accumulate within inflamed
tissues and correlates with disease severity (57, 58). Recently, the
activity of TSG-6 in OA synovial fluid has been demonstrated as a
biomarker for OA progression and the need for knee replacement
(59). The transfer of HCs to HMW-HA is a reversible and dynamic
event influenced by the availability of substrates, and smaller HA
fragments (oligosaccharides) can act as irreversible HC acceptors
and can disrupt highly adhesive properties of HC–HA (60). Stud-
ies of knockout mice lacking bikunin, which are unable to form
IαI, have revealed an inhibitory role for IαI heavy chains in com-
plement activation. Lack of IαI in mouse serum led to high levels
of complement activation and was reversible upon injection of
soluble IαI containing HCs (61). In humans, IαI does not appear
to be a potent inhibitor of complement activation, affecting only
early stages (62). In chronic inflammatory conditions such as RA,
where IαI heavy chains and HA fragments accumulate to high
levels and their effects may be more significant.
Tumor necrosis factor-stimulated gene 6 (TSG-6), which is
capable of binding to both IαI and HA, catalyzes the transfer of
HCs from the CS chain of IαI to HA by a trans-esterification
reaction to form HC–HA, and has also been well studied in the
context of ovulation (63, 64). The expression of TSG-6 is influ-
enced by a number of factors including TNF-α, IL-1β, TGF-β,
and LPS, in a highly cell type-dependent manner, and in many
cases is coordinated with the synthesis of HA (65). While induced
by inflammatory stimuli, TSG-6 has several protective features
including enhancing the anti-plasmin activity of IαI and inhibition
of MMPs and aggrecanases in cartilage (66, 67). Direct interaction
between TSG-6 and the glycosaminoglycan (GAG) binding site of
IL-8 has been shown to inhibit neutrophil migration by blocking
the interaction of IL-8 with heparan sulfate on endothelial cell
surfaces (68). The addition of TSG-6 to HA has been shown to
enhance CD44-dependent lymphoid cell adhesion to HA in flow
shear experiments (69). Interestingly, the Link module of TSG-6
alone can inhibit neutrophil migration and adhesion via exhibit-
ing anti-inflammatory effects independent of HA and IαI (70).
Recent studies have illustrated that: (1) the Link module of TSG-6
has binding sites for both HA and bikunin C4S; (2) TSG-6 is capa-
ble of binding non-covalently to HC1, HC2, and HC3 at affinities
greater than with HA; and (3) although TSG-6 alone is capable of
cross-linking HA into a dense, leukocyte-adhesive matrix, both the
degree of condensation and adhesion are reversible by addition of
IαI containing HC1 and HC2 (71). In a murine model of asthma,
TSG-6 null mice are resistant to airway hyperresponsiveness and
exhibit reduced levels of HA deposition, absence of HC–HA com-
plexes and decreased eosinophilic inflammation (72). Some of
these findings may be explained by the observation that airway
smooth muscle cells stimulated with poly (I:C) and TSG-6 pro-
duce increased levels of cell-associated HA cables than treatment
with poly (I:C) alone (73).
The adhesive properties of CD44+ cells to HA matrices depend
upon the composition of proteins bound to HA. HC–HA com-
plexes isolated from the synovial fluid of RA patients are highly
adhesive for CD44+ leukocytes. These HA complexes likely con-
tain several HA-binding proteins including HC3 and pentraxin-3,
but were found to be free of TSG-6 (74). However, it has been
recently shown that while TSG-6 enhances the interaction of HA
and CD44, the in vitro addition of IαI, TSG-6, and HCs (HC1 and
HC2) appears to counteract the enhanced binding of TSG-6–HA
complex alone (69, 71). This is in conflict with prior reports, but
suggests that HA-binding proteins themselves may regulate their
own interaction with HA (71, 74). As suggested by Day and de
la Motte, it is likely that the specific composition or organization
of HA–protein complexes dictates the outcome of many cell–HA
interactions (31).
Versican is a large CS-rich proteoglycan expressed at high levels
by proliferating cells and mesenchymal cells and is deposited into
the ECM during tissue remodeling and development. Versican is
a member of the lecticans, structurally similar proteins that also
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include aggrecan, neurocan, and brevican. Versican consists of an
amino-terminal globular domain (G1) and a carboxy-terminal
globular domain (G3), separated by several CS attachment sites
(GAG-α and GAG-β) between the two globular domains. The
G1 domain consists of an immunoglobulin-like fold and a pair
of link modules that bind five repeat disaccharides of HA with
high affinity. This interaction is further stabilized by link protein
itself, which binds both HA and versican (75, 76). Initial studies
of versican showed anti-adhesive properties, which now appear to
be mediated by the G1 domain (77–79). The G3 domain shares
homology with the selectins, containing two epidermal growth
factor (EGF) repeats, a C-type lectin domain, and a complement
regulatory region. Four alternative splicing isoforms of versican
(known as V0, V1, V2, and V3) result in truncation of the num-
ber of potential CS attachment sites (V1 and V2), with V3 lacking
them. All isoforms retain the G1 and G3 domains and therefore the
ability to bind to HA. The modular nature of versican can function
as a highly diverse molecular constituent of the ECM capable of
binding to a variety of factors involved in inflammatory processes.
Investigation into cancer growth and metastasis has impli-
cated versican as having a central role driven by inflamma-
tory stimuli. Versican, in either intact or fragmented forms
containing the G3 domain, can enhance tumor cell migration,
growth, and angiogenesis (80–82). In an in vitro screen for
carcinoma-derived factors capable of activating macrophages, ver-
sican was identified as a potent enhancer of metastatic growth
through TLR2 and co-receptors, TLR6 and CD14 (80). Versi-
can has been suggested to contribute to HA fragment activa-
tion of macrophages, and enhanced cancer metastasis through
induction of the hyaluronidases (83, 84). Several inflammation-
associated cytokines, including transforming growth factor β1, 2,
3, and platelet-derived growth factor (PDGF), have been shown to
increase biosynthetic levels of both versican and HA, while IL-1β,
and IFN-γ have been shown to reduce levels of versican (85–91).
Leukocyte trafficking and localization to regions of inflammation
mediated by interaction with cell-adhesion receptors functions as
a critical initiating step in the inflammatory cascade (92). Specific
CS chains on versican preferentially bind to chemokines known to
attract mononuclear leukocytes (93). Versican itself is capable of
binding to a number of cell surface receptors present on leukocytes
through interactions also mediated by CS chains, including both
L- and P-selectins and CD44 (93–95). Direct binding of P-selectin
glycoprotein ligand-1 (PSGL-1) by the G3 domain of versican has
also been shown to cause aggregation of leukocytes (82).
Together, these HA-binding proteins contribute to the mainte-
nance of tissue integrity and direct cell–ECM interactions in nor-
mal and pathological conditions. Many of the adhesive properties
of HA polymers depend upon the presence of HA-binding pro-
teins, and together with IαI, HCs, TSG-6, and versican contribute
to a dynamic extracellular environment capable of directing cell
adhesion and the production of inflammatory cytokines.
HYALURONAN CATABOLISM AND GENERATION OF HA
FRAGMENTS
Enzymatic degradation of HA is initiated by hyaluronidases
(hyaluronoglucosaminidases, or HYALs), a family of endo-
glycosidases that hydrolyze the β-1,4 linkages between
N-acetyl-hexosamines and glucuronic acid found in GAGs includ-
ing some activity toward chondroitin 4- and 6-sulfates, and unsul-
fated chondroitin (96, 97). In humans, genes for six hyaluronidase
family members have been identified to date: HYAL1–4, PH-20,
and HYALP1. With the exception of the pseudogene HYALP1,
each member encodes for protein products, and all but Hyal-3
have been shown to participate in either HA or CS catabolism [for
a review see Ref. (98)]. While Hyal-3 does not appear to have a
direct role in HA catabolism, it may be involved in an indirect fash-
ion (99, 100). In somatic tissues, Hyal-1 and Hyal-2 function as the
major hyaluronidases for HA degradation. In a rat model, exoge-
nous addition of HA indicated that some turnover takes place
locally at the site of intravenous injection, but the majority of
clearance occurred in the lymph nodes and liver (101). However,
other studies have suggested that local turnover is the major route
of HA clearance and clearance through the lymphatic system is rel-
atively minor when compared to local turnover by skin or skeletal
muscle (102). These discrepancies may exist due to the size of HA
used to measure local or lymphatic clearance, as it is likely that
low-molecular-weight HA within tissue can be removed from the
ECM by lymphatic drainage more easily than HMW–HA. Within
cells, HA turnover occurs within the lysosomal compartment by
concerted action of the endo-acting hyaluronidases, the lysoso-
mal exoglycosidases, β-glucuronidase, and β-hexosaminidase, in a
pH-sensitive manner (103, 104).
Of the six family members, Hyal-1 has been best studied. It
is widely expressed and is found in plasma and urine as well as
in several tissues including liver, kidney, spleen, and heart and
cleaves HA to tetra- and probably also hexasaccharides (105, 106).
Hyal1 is a 57-kDa glycoprotein that also occurs as a proteolyti-
cally processed 45-kDa form with two chains bound by a disulfide
bond. The biological significance of two forms of Hyal-1 is not
known, as both are present in tissues and cells while only the
57-kDa form is present in serum (107). Defects in HYAL1 were
identified as the genetic lesion in the lysosomal storage disorder
mucopolysaccharidosis IX (108). Loss of Hyal-1 activity results
in accumulation of HA in serum as well as within the lysosomes
of skin fibroblasts and macrophages (109). Once HA is within
the lysosome, the lysosomal exoglycosidases appear to share some
functional redundancy with Hyal-1 for HA turnover (97). Recom-
binant Hyal-1 has been reported to have a strict pH optimum near
3.7, with activity decreasing by ~75%± 0.5 pH (107). However,
several proteomics studies of lysosomes have not found Hyal-1
(or Hyal-2) in their analysis. This discrepancy may be due to the
method of protein detection as most of these studies rely upon
the fact that the majority of lysosomal hydrolases are targeted to
the lysosome by the mannose 6-phosphate (M6P) pathway [for
more details, see review in Ref. (110)], and therefore have utilized
immobilized M6P-receptors as a purification method (111–120).
Consequently, with the exception of one study (120), proteins
trafficked to the lysosome by M6P-independent mechanisms are
missing from these data sets. Other in vitro and in vivo studies have
shown that Hyal-1, either in culture medium or serum, is taken up
by endocytosis and does reach the endosomal–lysosomal network.
This compartment, however, does not contain the classical late
lysosomal hydrolases β-galactosidase or N -acetylglucosaminidase,
and likely represents a late endosome (121, 122). These data fit
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well with the high levels of Hyal-1 observed in plasma and sug-
gest that newly synthesized Hyal-1 reaches lysosomes through a
secretion-recapture mechanism. The function of Hyal-1 within
serum remains unclear.
Hyal-2 shares many of the features of Hyal-1: it is a 55-kDa gly-
coprotein widely distributed in a number of tissues, acid active, and
found in two forms. Although it is frequently reported to be lyso-
somal, significant controversy exists around this point (123–125).
Hyal-2 contains a glycosylphosphatidylinositol (GPI) linkage that
tethers it to membrane surfaces where it can serve as the receptor
for the jaagsiekte sheep retrovirus (84, 126, 127). GPI-anchored
Hyal-2 has hyaluronidase activity when it is on the surface of
human platelets (34). In certain cell types, a soluble, intracellu-
lar form lacking the GPI anchor has also been reported (128,
129). Initial studies of soluble Hyal-2 activity indicated that the
enzyme is functional only in a narrow pH range around 3.7, sim-
ilar to Hyal-1. Despite having a high degree of primary sequence
homology to Hyal-1, Hyal-2 cleaves HMW–HA to generate 20-
kDa fragments (approximately 50 disaccharides) in vitro (123,
125). A study of Hyal-2 expressed in HEK293 cells indicates strong
membrane co-localization of Hyal-2 and CD44 with a pH opti-
mum of 6.0 for membrane fractionated Hyal-2. Although some
HA fragments generated by Hyal-2 were internalized, the majority
was released into the medium (121). This is consistent with the
finding that in breast cancer cells, Hyal-2 forms a complex with
CD44 and the Na+–H+ exchanger 1 (NHE1), and HA degradation
by Hyal-2 depends upon its interaction with CD44 at the mem-
brane surface. However, controversy exists as to whether CD44
is present on the surface of platelets (130, 131). In culture, the
interaction of CD44 and NHE1 leads to extrusion of H+ ions
and a decrease in extracellular pH to 6.6 (132). Possibly, the dis-
tribution of Hyal-2 as either membrane-associated or soluble is
cell-type or activation-state specific, and insertion into a lipid
membrane can affect both the localization and the activity range
of Hyal-2.
Degradation of HA by Hyal-1 primarily takes place within
cells, and depends upon the ability of CD44 or other HA recep-
tors to internalize HA fragments. Although significant levels of
Hyal-1 are present in serum, to date it has not been shown to be
functionally active in circulation. Interestingly, MPS IX patients
deficient in Hyal-1 have been reported with plasma HA levels at
40 times normal (109). Thus it is unclear whether circulating Hyal-
1 could potentially contribute to HA fragmentation. At this point
in time, Hyal-1 appears to primarily contribute to intracellular HA
turnover.
The ability of the hyaluronidases to depolymerize HA seems to
be highly dependent on compartment and contribution of HA-
binding proteins. The discrepancies in pH optimum reported in
the literature may suggest that in a low pH environment, certain
sizes of HA are easily degraded by Hyal-1 and Hyal-2 without
the assistance of HA-binding proteins. It has been suggested that
HMW-HA exists as a supramolecular structure capable of tran-
sitioning between secondary and tertiary structures in in vitro
solutions (133, 134). However, other studies indicate that these
interactions may not occur. Data demonstrating a lack of intra-
chain interactions open to competition, and an absence of amide-
carboxylate hydrogen bonds required to form a twofold helical HA
chain necessary for proposed models of secondary and tertiary
HA structures, together suggest that intra-molecular structures
are unlikely (135, 136). The structure of HA in vivo is likely to
be dictated by the specificity, degree, and hierarchy of protein–
HA interactions, and the ability of the hyaluronidases to degrade
HA probably depends upon the conformation of HA chains. The
finding of Hyal-2 in complex with CD44 at the plasma membrane
is suggestive that HA-binding proteins can enhance the activ-
ity of HA degrading enzymes, and CD44 binding may provide
Hyal-2 with a preferable conformation of HA. While Hyal-1 and
Hyal-2 have been shown to prefer to cleave HA to tetrasaccha-
rides and 50 disaccharides, respectively, these experiments have
been performed in vitro for long periods of time and in most
cases with exogenous HA free of HA-binding proteins. Given
that neither enzyme has been shown to exhibit processivity, the
sizes generated by Hyal-2 at the cell surface are more likely to be
polydisperse and dependent upon the availability of HA-binding
proteins.
While the hyaluronidases discussed above are at present the
most plausible sources of HA fragments, they are not likely to be
the only contributors. Recently, KIAA1199, a gene of unknown
function involved in non-syndromic hearing loss and several
forms of cancer has been identified as a HA-binding protein
that contributes to HA degradation in cultured skin fibroblasts
(137, 138). Interestingly, the authors show that siRNA-mediated
knockdown of CD44 or Hyal-2 had no effect on HA degradation.
Further, Hyal-1 did not appear to be expressed in Detroit 551 skin
fibroblasts, and the majority of the HA depolymerization was lost
upon KIAA1199 knockdown. However, it is important to note that
although KIAA1199 appears to co-localize and co-precipitate with
clathrin heavy chain, the authors were only able to detect depoly-
merized HA within media and were unable to detect fragments
within the cell (137, 138). Future studies will determine whether
KIAA1199 truly is a HA degrading enzyme.
Hyaluronan has long been suggested to protect articular tis-
sues by absorbing ROS capable of degrading components of
the ECM in vitro (139, 140). An additional mechanism sug-
gested in the literature that could lead to HA fragmentation is
the accumulation of ROS under conditions of injury or patho-
logical inflammation. Accumulation of ROS in chronic inflam-
matory conditions has been noted, and direct depolymerization
of HA by ROS has been illustrated largely in vitro, with some
exceptions (141–146). In an epithelial airway culture system, xan-
thine/xanthine oxidase generation of ROS led to HA degrada-
tion and tissue kallikrein-mediated EGF receptor activation (147).
However, ROS species themselves are capable of stimulating Hyal-
2 gene expression via p38MAPK. In lentiviral-mediated Hyal-2
knockdown of cells exposed to ROS, HA depolymerization was
not observed (148). Other species, including O−2 and NO are
present locally in inflammatory tissues and may recombine to
produce peroxynitrite, which specifically degrades the HA, but
not heparin/heparan sulfate (149–151). The contribution of ROS
species to HA fragment generation will ultimately depend upon
the relative ratio of these species, HA, anti-oxidants, and other
substrates within the ECM. HA fragments generated directly by
ROS species are functionally equivalent to enzymatic products is
currently not known.
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HYALURONAN SIGNALING RECEPTORS
CD44 is a type I transmembrane glycoprotein and is widely
regarded as the major cell-surface HA binding protein (152).
Widely studied in several contexts, CD44 interactions with HA
have important roles in tumor metastasis, lymphocyte adhesion,
T cell signaling, angiogenesis, and inflammation (153–156). CD44
contains a short cytoplasmic tail with multiple phosphorylation
sites, a transmembrane domain, an extensively glycosylated vari-
able region, and an amino-terminal HA binding domain contain-
ing a Link module (157–159). CD44 exhibits significant protein
diversity partially due to variable splicing of exons, each encod-
ing for a segment of the extracellular domain, and over a dozen
isoforms have been discovered. Of the variable forms of CD44,
the most common is termed hematopoietic or standard CD44
(CD44s, CD44H). The diversity of CD44 is further elaborated by
the extent to which it is glycosylated. It contains up to two GAG
attachment sites (CS or HS), and extensive N- and O-linked gly-
cosylation alone can account for the majority of the molecular
weight of CD44s. Many of the N-linked sites are found within the
HA binding domain, and glycosylation of CD44 negatively regu-
lates its ability to bind HA in some cell types (160). CD44 has been
shown to require activation for high affinity HA binding, and one
mechanism involves the enzymatic removal of terminal sialic acid
from two N-linked glycans in the HA binding domain (161–163).
Crosslinking of HA by binding proteins, such as TSG-6, can sig-
nificantly alter the way in which HA is structured within the ECM
and can alter the affinity of CD44 for HA (69, 158, 164).
CD44 is expressed on many cell types that contribute to inflam-
mation including leukocytes, neutrophils, macrophages, chondro-
cytes, fibroblasts, epithelial, and endothelial cells. While the GAGs
of CD44 can bind to cytokines, growth factors, and ECM proteins
such as fibronectin, the majority of the functions of CD44 depend
upon its ability to bind to HA (165). Just as the size of HA seems to
dictate whether it functions as a pro- or anti-inflammatory mol-
ecule, studies have suggested CD44 shares contrasting roles. The
molecular mechanisms dictating CD44s function may be driven
by its affinity for HA. Several stimuli have been shown to activate
or dampen the affinity of CD44 for HA. While if the transition
from low- to high-affinity binding state (or vice versa) involves a
conformational change has not been directly shown, it has been
established that HA oligomers cause a ligand-induced conforma-
tional change and HA may have two mutually exclusive modes of
binding to CD44 (159). Dimerization of CD44 may lead to acti-
vation of HA binding, and binding at the cell surface is the result
of multiple weak HA–CD44 interactions, which are influenced
by the size of the HA ligand (166–168). Interestingly, stability of
HA binding appears to be size dependent and it is possible that
stability itself may participate in signaling, which could explain
the relationship between molecular weight and signaling (169). T
cells are stimulated to bind HA by the cytokines IL-2 and TNF,
as well as by chemokines such as MIP-1B, IL-8, and RANTES
(170, 171). Monocytes can be stimulated to bind HA by a num-
ber of cytokines such as TNF-α, IL-1α, IL-1β, IL-3, IFN-γ, and
LPS (163, 171–173). By contrast, some molecules including IL-4
and IL-13 inhibit CD44–HA binding (172, 174, 175). Antibodies
to CD44 that interfere in HA binding attenuate inflammation in
animal models of IBDs. In particular, CD44v7 has been strongly
implicated in murine models of colitis as a potent inflammatory
mediator. Disrupting CD44v7 isoforms with blocking antibodies
induces apoptosis of mononuclear cells in both murine models of
IBD as well as in monocytes isolated from inflamed mucosa of IBD
patients (176–178). Mice deficient in all isoforms of CD44 develop
normally, suggesting that other receptors can compensate for its
loss (179). While CD44 is regarded as the primary cell-surface
receptor for HA in many cell types, investigation into the mech-
anisms underlying HA fragment signaling has demonstrated that
HA fragments are capable of signaling independently of CD44 (3,
48, 180, 181).
Toll-like receptors function as surveillance receptors, interact-
ing with a number of microbial-derived molecules and activating
the innate immune system in response to pathogen-associated
molecular patterns (PAMPs). Increasingly, the TLRs are also
shown to sense damage-associated molecular patterns (DAMPs) in
response to injury as well (182). The idea that endogenous matrix
degradation products act as regulators of cellular processes is not
a new one, but with respect to GAG fragments, the role of HA is
the best studied (183). HA is a component of the cellular coat on
some pathogens including both groups A and C streptococcus, some
strains of Escherichia coli, and Pasteurella multocida, and many of
these pathogens also express hyaluronidases (184–186). The pres-
ence of a HA coat likely assists in evasion by the immune system,
while the hyaluronidase enzymes may aid in colonization of the
host. HA fragments functioning as DAMPs interact with TLRs,
and thereby compete with HMW–HA to initiate receptor signal-
ing. Studies of lysosomal storage disorders, where GAG fragments
accumulate within the cell, have suggested that incomplete GAG
degradation products are associated with increased activation of
TLRs (187–189).
Ten TLR genes have been identified in humans to date, and
both TLR4 – the primary signaling receptor for lipopolysaccha-
rides, and TLR2 – a recognition receptor for mycoplasma and
gram positive bacteria, are involved in recognition of fragmented
HA (3, 35, 43, 48, 83, 190). While an increasing number of
studies have shown that TLRs are involved in HA signaling, the
underlying mechanisms remain unclear. In dendritic cells, data
suggest that TLR4 is required for recognizing HA fragments of
4-, 6-, and 8-sugars, and recognition is independent of CD44,
TLR2, or receptor for HA-mediated mobility (RHAMM) (36,
44). However, studies by Noble and colleagues have shown that
macrophages isolated from either TLR2 or TLR4 knock out mice
are still capable of chemokine gene expression induced by HA
fragments, while macrophages from TLR2/4 double knockouts
are not. Using a non-infectious bleomycin-induced lung injury
model, they also demonstrated that TLR2/4 double knockout mice
are protected from acute inflammation due to an impaired ability
of macrophages to respond to HA fragments, but at the expense
of epithelial cell repair (3).
The data presented by Noble’s group showed a requirement
for MyD88, a downstream effector molecule shared by the TLRs,
and for HA fragment signaling; HA-TLR signaling was abolished
in MyD88-deficient macrophages (3). However, a recent study
indicates that HA fragments of ~200 kDa are capable of inducing
type I interferons by a TLR4 MyD88-independent pathway (191).
These differences observed in signaling complex requirements
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may depend upon the size of HA used (135- vs. 200-kDa) or the
spectrum of receptors present at the cell surface during the exper-
iments. The specific receptor complexes and signaling pathways
engaged appear to be highly cell type dependent. Taylor et al. have
shown that although CD44, in some contexts, does not appear to
be required for TLR4-mediated HA signaling, it can function in
an enhancing role. The adapter molecules CD14 and MD-2 are
required for TLR4 recognition of LPS, but CD14 is dispensable for
HA signaling in cultured cells (35).
Despite a lack of biophysical evidence that TLRs bind directly
to HA or other GAG fragments, interplay between these molecules
as mediators of the inflammatory process is clear. Although data
support CD44-independent TLR signaling by HA fragments in
some cell types, it is not clear if there is competition between these
receptors for HA fragment ligands or if they work in a co-operative
fashion. Future studies are needed to define the signaling pathways
activated by different sizes of HA fragments and the receptors
utilized.
EVIDENCE FOR IN VIVO IMPORTANCE OF HA FRAGMENTS
In vitro studies have defined multiple signaling properties of
HA fragments that occur in a cell type-specific manner and
are mediated by a complicated arrangement of receptors. It is
clear, however, that HA fragments possess important biologi-
cal roles in innate immunity. A number of animal models have
aided our understanding of how HA modulates inflammation
in injury and disease. In a non-infectious lung injury model,
HA fragments accumulate in lung tissue and require CD44+
macrophages for clearance before the tissue can be repaired (4).
HA fragments are cleared as inflammation is resolved in wild-
type mice, but fragments accumulate in CD44-deficient animals.
The inability to remove HA fragments from the lung epithelium
results in gross inflammation and impaired clearance of apop-
totic neutrophils (4). At the cell surface, HMW–HA protects lung
epithelium from injury through activation of NF-κB and suppres-
sion of apoptosis. Disruption of HA–TLR interactions results in
loss of the protective effect of HMW–HA, and tissue injury is
exacerbated (3).
HA-binding proteins have also been implicated in resolution
of lung inflammation. IαI containing HCs expressed in the liver
and normally secreted into serum, enter the lung through vascu-
lar leakage during inflammation. In bleomycin-challenged mice,
IαI and HA normally appear to co-localize within inflamed lungs
whereas in mice lacking IαI, increased levels of HA and cellu-
lar inflammation were noted. Together this suggests that HA–HC
complexes may contribute to the resolution of lung injury (61,
192). Previous studies have shown HA–HC complexes are higher
affinity for CD44 (74), and it is plausible that these HA-binding
proteins work together to mediate tissue homeostasis within the
lung. Some HA–HC preparations do not exhibit enhanced CD44
binding, and it is likely that the properties of HA–HC depend
upon its exact composition of HA-binding proteins as well as the
background of the cells involved (71). HMW–HA and CD44 inter-
actions support cell survival, and in cases of injury, fragments
accumulate and contribute to induction of inflammation. Clear-
ance of HA fragments, the uptake of apoptotic neutrophils by
macrophages, and restoration of HMW–HA pro-survival signals
all depend upon CD44, and HA homeostasis is required to resolve
lung inflammation and initiate tissue repair.
Though not discussed within the scope of this article, inflam-
matory mediators can promote angiogenesis, which facilitates
chronic inflammation. New blood vessels can sustain a chronic
inflammatory response by supplying a source of oxygen and nutri-
ents to inflamed tissue and through transport of new inflamma-
tory cells to the site of inflammation. HA polymers regulate the
growth of new blood vessels through interactions with endothelial
cells. HMW–HA is anti-angiogenic and inhibits endothelial cell
proliferation, while fragmented HA is a pro-angiogenic stimula-
tor. Endothelial cell interactions with HA are mediated in concert
by CD44 and RHAMM (6, 7). Loss of CD44 disrupts angiogenesis
in vivo, and this effect is due to the loss of CD44 expression in
endothelial cells, as wild-type leukocytes or bone marrow-derived
progenitor cells were unable to rescue the diminished angiogenic
response. Interestingly, the endothelial cells deficient in CD44 are
still capable of binding HA and exhibit normal migration, possi-
bly due to compensation by RHAMM in these animals. In mice
treated with an anti-CD44 antibody shown to block HA bind-
ing, neovascularization is drastically impaired, and new vessels
cannot properly assemble endothelium-lined tubes (5). In tissues
where new vessels are formed or become leaky due to injury, IαI
from serum is readily available and can alter the adhesive prop-
erties of HA. In an in vivo matrigel angiogenesis model, mice
lacking IαI exhibit drastically reduced vessel growth (192). How-
ever, it is worth noting that HA–HC complexes purified from the
amniotic membrane appear to be anti-angiogenic, perhaps sug-
gesting a different composition or organization (193). Endothelial
cell interactions with a HA matrix depend upon the CD44–HA
interactions that can be enhanced by IαI, and other HA-binding
proteins, during vessel formation. Disruption of cell–matrix inter-
actions leads to disrupted tube assembly and decreased stability of
newly formed vessels.
Fragmentation of HA was recognized as one of the earliest
biological markers for RA, and many animal models of RA are
induced by ECM components such as type II collagen or aggrecan
(14, 194, 195). Large amounts of HA containing HCs from IαI are
found in the synovial fluid of RA patients, and HA–HC complexes
contained within the synovium are highly adhesive for infiltrating
leukocytes (74). Interestingly, mice incapable of forming HA–HC
complexes, or treated with an anti-CD44 antibody, are more resis-
tant to arthritis than wild-type littermates (196–198). By contrast,
in a proteoglycan-induced arthritis model, mice deficient in CD44
only exhibit moderate to no resistance (199, 200). HA complexes
containing TSG-6 and IαI accumulate to high levels at inflam-
matory sites and may support CD44-mediated leukocyte rolling
and adhesion, while potentially having anti-inflammatory effects
(69, 155, 201). High levels of TSG-6 have been reported in the
secretory granules of mast cells within the inflamed joint tissues
of mice, and intra-articular injection or cartilage-specific expres-
sion of TSG-6 have significant protective effects (66, 202, 203). It
is possible that TSG-6 mediated crosslinking of HA results in a
pro-adhesive but anti-inflammatory matrix for CD44+ cells (69).
In the absence of CD44, the initial phases of leukocyte recruitment
within inflamed synovial vessels are altered, and leukocytes appear
to roll rather than adhere (204, 205). Leukocytes deficient in CD44
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do not appear to interact as tightly with these HA complexes, sug-
gesting that reduced adhesion contributes to the delayed onset of
arthritis in these animals. Importantly, wild-type mice treated with
anti-CD44 antibodies cross-link cell surface CD44, which rapidly
disables leukocyte rolling. Antibody cross-linking of CD44 was
followed by platelet deposition on the surface of granulocytes in
the vascular beds of inflamed synovial tissue, and platelet-coated
granulocytes were cleared from circulation leading to resolution
of inflammation (205). These studies, in which different behaviors
are observed when CD44 is either absent or blocked, are indicative
of important differences reported in the literature with regards to
the effects of HA fragments.
More extensive studies are needed to fully understand the spe-
cific molecular interactions between HA, HA-binding proteins,
and HA receptors in the initiation and resolution of inflamma-
tion. The tissue microenvironment contributes significantly in
regulating the inflammatory process. Defining the mechanisms
by which inflammatory and protective HA fragments are gener-
ated, and how binding proteins influence their effects, will enable
us to better understand the progression of inflammatory disease
and perhaps reveal new therapeutic targets.
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